Former President of Calix Corporation, parent company to Pharm-Eco Laboratories Inc. From 2004 until 2008. Chief Executive Officer and President for DNAPrint Genomics Inc. Successfully completed formation of several private and public companies in the genetics, chemistry and pharmaceutical fields. Has been a part of the development of four successful drugs that include: Amprenavir (VX-478), Emtricitabine (FTC), Altretamine (Hexalen), Zalcitabine (DDC). Mr. Gabriel sits on the boards of several companies, including WindGap Medical and Predictive Oncology, Inc. (NASDAQ: POAI), 48 Hour Discovery, Inc.